All Stories

  1. Hype or hope? The strange case of platinum salts’ renaissance in breast cancer

    Article • Expert Review of Anticancer Therapy, November 2019, Taylor & Francis

    Fabio Puglisi

  2. The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

    Article • Clinical Breast Cancer, August 2019, Elsevier

    Fabio Puglisi

  3. Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors

    Article • International Journal of Molecular Sciences, July 2019, MDPI AG

    Fabio Puglisi

  4. Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer

    Article • Cancers, June 2019, MDPI AG

    Fabio Puglisi

  5. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside

    Article • Cancers, June 2019, MDPI AG

    Fabio Puglisi

  6. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

    Article • Annals of Oncology, May 2019, Elsevier

    Fabio Puglisi

  7. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

    Article • Clinical Breast Cancer, April 2019, Elsevier

    Fabio Puglisi

  8. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients

    Article • Journal of Cachexia Sarcopenia and Muscle, February 2019, Wiley

    Fabio Puglisi

  9. Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

    Article • Cancer Treatment Reviews, February 2019, Elsevier

    Fabio Puglisi

  10. Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers – ESEMPiO study

    Article • Future Oncology, January 2019, Future Medicine

    Fabio Puglisi

  11. Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation

    Article • Cancer Treatment Reviews, January 2019, Elsevier

    Fabio Puglisi

  12. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy

    Article • International Journal of Cancer, December 2018, Wiley

    Fabio Puglisi

  13. Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients

    Article • Melanoma Research, December 2018, Wolters Kluwer Health

    Fabio Puglisi

  14. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

    Article • BMC Cancer, September 2018, Springer Science + Business Media

    Fabio Puglisi

  15. Prognostic evaluation in palliative care: final results from a prospective cohort study

    Article • Supportive Care in Cancer, September 2018, Springer Science + Business Media

    Fabio Puglisi

  16. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme

    Article • Journal of Neuro-Oncology, August 2018, Springer Science + Business Media

    Fabio Puglisi

  17. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM)

    Article • European Journal of Cancer, August 2018, Elsevier

    Fabio Puglisi

  18. Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey

    Article • The Breast, August 2018, Elsevier

    Fabio Puglisi

  19. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

    Article • Annals of Oncology, August 2018, Elsevier

    Fabio Puglisi

  20. Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study

    Article • Journal of Cancer Research and Clinical Oncology, July 2018, Springer Science + Business Media

    Fabio Puglisi

  21. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    Article • New England Journal of Medicine, July 2018, New England Journal of Medicine (NEJM/MMS)

    Fabio Puglisi

  22. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype

    Article • Cancer Treatment Reviews, July 2018, Elsevier

    Fabio Puglisi

  23. Reply to the letter “Body mass index and clinical outcomes in trastuzumab-treated metastatic breast cancer patients: An alternative explanation for the lack of association”

    Article • The Breast, June 2018, Elsevier

    Fabio Puglisi

  24. Determinants of Last-line Treatment in Metastatic Breast Cancer

    Article • Clinical Breast Cancer, June 2018, Elsevier

    Fabio Puglisi

  25. Atezolizumab for the treatment of breast cancer

    Article • Expert Opinion on Biological Therapy, May 2018, Taylor & Francis

    Professor Fabio Puglisi, Fabio Puglisi

  26. MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme

    Article • Future Oncology, April 2018, Future Medicine

    Fabio Puglisi

  27. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy

    Article • Future Oncology, April 2018, Future Medicine

    Fabio Puglisi

  28. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results

    Article • The Breast, April 2018, Elsevier

    Fabio Puglisi

  29. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer

    Article • The Breast, February 2018, Elsevier

    Fabio Puglisi

  30. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype

    Article • International Journal of Molecular Sciences, December 2017, MDPI AG

    Giovanni Lo Re, Fabio Puglisi

  31. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression

    Article • Cancer Treatment Reviews, December 2017, Elsevier

    Fabio Puglisi

  32. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study

    Article • Clinical Breast Cancer, December 2017, Elsevier

    Fabio Puglisi

  33. Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis

    Article • Oncotarget, November 2017, Impact Journals, LLC

    Fabio Puglisi

  34. Efficacy and safety of eribulin in taxane-refractory patients in the ‘real world’

    Article • Future Oncology, May 2017, Future Medicine

    Professor Fabio Puglisi, Fabio Puglisi

  35. Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

    Article • Breast Cancer Research and Treatment, April 2017, Springer Science + Business Media

    Fabio Puglisi

  36. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

    Article • Breast Cancer Research and Treatment, March 2017, Springer Science + Business Media

    Fabio Puglisi

  37. Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy

    Article • Future Oncology, February 2017, Future Medicine

    Professor Fabio Puglisi, Fabio Puglisi

  38. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

    Article • The Breast, February 2017, Elsevier

    Fabio Puglisi

  39. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle

    Article • Expert Opinion on Biological Therapy, January 2017, Taylor & Francis

    Fabio Puglisi

  40. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies

    Article • European Journal of Cancer, January 2017, Elsevier

    Fabio Puglisi

  41. Bevacizumab in breast cancer

    Article • Future Oncology, November 2016, Future Medicine

    Prof. Paolo Marchetti, Professor Fabio Puglisi, Fabio Puglisi

  42. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

    Article • Annals of Oncology, November 2016, Elsevier

    Fabio Puglisi

  43. The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

    Article • British Journal of Cancer, November 2016, Springer Science + Business Media

    Fabio Puglisi

  44. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00

    Article • Journal of Clinical Oncology, October 2016, American Society of Clinical Oncology (ASCO)

    Fabio Puglisi

  45. BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress

    Article • Cell Death and Disease, September 2016, Springer Science + Business Media

    Fabio Puglisi

  46. Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example

    Article • OncoTargets and Therapy, August 2016, Dove Medical Press

    Professor Fabio Puglisi, Fabio Puglisi

  47. Do platinum salts fit all triple negative breast cancers?

    Article • Cancer Treatment Reviews, July 2016, Elsevier

    Fabio Puglisi

  48. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

    Article • Journal of Clinical Oncology, May 2016, American Society of Clinical Oncology (ASCO)

    Fabio Puglisi

  49. Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?

    Article • Cancer Treatment Reviews, May 2016, Elsevier

    Fabio Puglisi

  50. Adjuvant ovarian function suppression and cognitive function in women with breast cancer

    Article • British Journal of Cancer, April 2016, Springer Science + Business Media

    Fabio Puglisi

  51. Translational and clinical research highlights from the 38th San Antonio Breast Cancer Symposium

    Article • Future Oncology, April 2016, Future Medicine

    Fabio Puglisi

  52. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

    Article • March 2016, Springer Science + Business Media

    Fabio Puglisi

  53. Current challenges in HER2-positive breast cancer

    Article • Critical Reviews in Oncology/Hematology, February 2016, Elsevier

    Fabio Puglisi

  54. Hepatitis B and cancer: A practical guide for the oncologist

    Article • Critical Reviews in Oncology/Hematology, February 2016, Elsevier

    Fabio Puglisi

  55. Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review

    Article • Cancer Treatment Reviews, February 2016, Elsevier

    Fabio Puglisi

  56. Corrigendum to “Gene expression profiling in breast cancer: A clinical perspective” [The Breast 22 (2013) 109–120]

    Article • The Breast, February 2016, Elsevier

    Fabio Puglisi

  57. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence

    Article • Expert Review of Anticancer Therapy, December 2015, Taylor & Francis

    Fabio Puglisi

  58. Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy

    Article • Clinical & Experimental Metastasis, September 2015, Springer Science + Business Media

    Fabio Puglisi

  59. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

    Article • The Lancet Oncology, July 2015, Elsevier

    Fabio Puglisi

  60. Patterns of Care and Clinical Outcomes of First‐Line Trastuzumab‐Based Therapy in HER2‐Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

    Article • The Oncologist, June 2015, Alphamed Press

    Fabio Puglisi

  61. Treatment of Metastatic Breast Cancer in a Real‐World Scenario: Is Progression‐Free Survival With First Line Predictive of Benefit From Second and Later Lines?

    Article • The Oncologist, May 2015, Alphamed Press

    Fabio Puglisi

  62. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

    Article • The Lancet, May 2015, Elsevier

    Fabio Puglisi

  63. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients

    Article • Future Oncology, May 2015, Future Medicine

    Fabio Puglisi

  64. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells

    Article • Oncology Reports, March 2015, Spandidos Publications

    Fabio Puglisi

  65. MR mammography using diffusion-weighted imaging in evaluating breast cancer: a correlation with proliferation index

    Article • La radiologia medica, March 2015, Springer Science + Business Media

    Fabio Puglisi

  66. Pattern of metastasis and outcome in patients with breast cancer

    Article • Clinical & Experimental Metastasis, January 2015, Springer Science + Business Media

    Fabio Puglisi

  67. Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study

    Article • Annals of Surgical Oncology, January 2015, Springer Science + Business Media

    Fabio Puglisi

  68. Looking for predictive markers in breast cancer

    Article • The Lancet Oncology, January 2015, Elsevier

    Fabio Puglisi

  69. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomi...

    Article • The Lancet Oncology, October 2014, Elsevier

    Dr Norbert W Marschner, Fabio Puglisi

  70. Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?

    Article • OncoTargets and Therapy, September 2014, Taylor & Francis

    Dr Chiara Lestuzzi, Dr MARIA GRAZIA BALDIN, Professor Fabio Puglisi, Fabio Puglisi

  71. Follow-up of patients with early breast cancer: Is it time to rewrite the story?

    Article • Critical Reviews in Oncology/Hematology, August 2014, Elsevier

    Fabio Puglisi

  72. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Article • New England Journal of Medicine, July 2014, New England Journal of Medicine (NEJM/MMS)

    Fabio Puglisi

  73. Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM)

    Article • Annals of Oncology, June 2014, Elsevier

    Fabio Puglisi

  74. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real‐World Scenario

    Article • The Oncologist, May 2014, Alphamed Press

    Fabio Puglisi

  75. Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study

    Article • Supportive Care in Cancer, April 2014, Springer Science + Business Media

    Dr FEDERICA EDITH PISA, Fabio Puglisi

  76. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole

    Article • British Journal of Cancer, January 2014, Springer Science + Business Media

    Fabio Puglisi

  77. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients

    Article • November 2013, Bioscientifica

    Fabio Puglisi

  78. Primary Therapy in Breast Cancer: What Have We Learned from Landmark Trials?

    Article • Women s Health, November 2013, SAGE Publications

    Fabio Puglisi

  79. Factors affecting patient's perception of anticancer treatments side-effects: an observational study

    Article • Expert Opinion on Drug Safety, September 2013, Informa Healthcare

    Fabio Puglisi

  80. Exploring Prognostic and Predictive Value of Biomarkers: The Example of Thymidine Phosphorylase in Breast Cancer

    Article • The Journal of OncoPathology, September 2013, Optimal Clinical, Ltd.

    Fabio Puglisi

  81. Bevacizumab in older patients with advanced colorectal or breast cancer

    Article • Critical Reviews in Oncology/Hematology, July 2013, Elsevier

    Fabio Puglisi

  82. One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasis

    Article • Virchows Archiv, June 2013, Springer Science + Business Media

    Fabio Puglisi

  83. Risk factors and survival outcomes in patients with brain metastases from breast cancer

    Article • Clinical & Experimental Metastasis, June 2013, Springer Science + Business Media

    Fabio Puglisi

  84. Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?

    Article • Clinical Breast Cancer, June 2013, Elsevier

    Fabio Puglisi

  85. Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma

    Article • Melanoma Research, April 2013, Wolters Kluwer Health

    Fabio Puglisi

  86. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial

    Article • The Breast, April 2013, Elsevier

    Fabio Puglisi

  87. Gene expression profiling in breast cancer: A clinical perspective

    Article • The Breast, April 2013, Elsevier

    Fabio Puglisi

  88. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors

    Article • Anti-Cancer Drugs, February 2013, Wolters Kluwer Health

    Fabio Puglisi

  89. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients

    Article • World Journal of Gastroenterology, January 2013, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Fabio Puglisi

  90. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole

    Article • Breast Cancer Research and Treatment, November 2012, Springer Science + Business Media

    Fabio Puglisi

  91. Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers

    Article • Biochemical and Biophysical Research Communications, July 2012, Elsevier

    Fabio Puglisi

  92. Overcoming Treatment Resistance in HER2-Positive Breast Cancer

    Article • Drugs, June 2012, Springer Science + Business Media

    Fabio Puglisi

  93. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

    Article • Breast Cancer Research and Treatment, April 2012, Springer Science + Business Media

    Fabio Puglisi

  94. Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy

    Article • Anti-Cancer Drugs, March 2012, Wolters Kluwer Health

    Fabio Puglisi

  95. Expression of Dicer and Drosha in triple-negative breast cancer

    Article • Journal of Clinical Pathology, January 2012, BMJ

    Fabio Puglisi

  96. B-Cell Lymphoma Presenting as Acute Pancreatitis

    Article • Pancreatology, December 2011, Elsevier

    Fabio Puglisi

  97. Treatment of HER2-positive breast cancer: current status and future perspectives

    Article • Nature Reviews Clinical Oncology, November 2011, Springer Science + Business Media

    Fabio Puglisi

  98. Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines

    Article • Oncology Reports, May 2011, Spandidos Publications

    Fabio Puglisi

  99. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

    Article • Journal of Experimental & Clinical Cancer Research, May 2011, Springer Science + Business Media

    Fabio Puglisi

  100. Adjuvant endocrine therapy in postmenopausal breast cancer patients: Does hormone receptor status influence decision-making?

    Article • Critical Reviews in Oncology/Hematology, February 2011, Elsevier

    Fabio Puglisi

  101. First-line chemotherapy with or without biologic agents for metastatic breast cancer

    Article • Critical Reviews in Oncology/Hematology, November 2010, Elsevier

    Fabio Puglisi

  102. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer

    Article • The Breast, October 2010, Elsevier

    Fabio Puglisi

  103. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Article • Journal of Clinical Oncology, July 2010, American Society of Clinical Oncology (ASCO)

    Fabio Puglisi

  104. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation

    Article • Cancer, January 2010, Wiley

    Fabio Puglisi

  105. Hormone therapy in elderly breast cancer patients with comorbidities

    Article • Critical Reviews in Oncology/Hematology, January 2010, Elsevier

    Fabio Puglisi

  106. What Does Similarity Mean in Clinical Trials?

    Article • Journal of Clinical Oncology, November 2009, American Society of Clinical Oncology (ASCO)

    Fabio Puglisi

  107. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era

    Article • Anti-Cancer Drugs, July 2009, Wolters Kluwer Health

    Fabio Puglisi

  108. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer

    Article • Anti-Cancer Drugs, April 2009, Wolters Kluwer Health

    Fabio Puglisi

  109. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients

    Article • Critical Reviews in Oncology/Hematology, February 2009, Elsevier

    Fabio Puglisi

  110. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

    Article • Annals of Oncology, February 2009, Elsevier

    Fabio Puglisi

  111. From the podium to the patient: bringing the 2008 ASCO meeting to the clinic

    Article • Anti-Cancer Drugs, November 2008, Wolters Kluwer Health

    Fabio Puglisi

  112. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer

    Article • Annals of Oncology, September 2008, Elsevier

    Fabio Puglisi

  113. Cognitive functions and elderly cancer patients receiving anticancer treatment: A prospective study

    Article • Critical Reviews in Oncology/Hematology, July 2008, Elsevier

    Fabio Puglisi

  114. Expression of periostin in human breast cancer

    Article • Journal of Clinical Pathology, April 2008, BMJ

    Fabio Puglisi

  115. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer

    Article • Expert Review of Anticancer Therapy, March 2008, Taylor & Francis

    Fabio Puglisi

  116. Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology

    Article • Anti-Cancer Drugs, February 2008, Wolters Kluwer Health

    Fabio Puglisi

  117. Information to cancer patients: a questionnaire survey in three different geographical areas in Italy

    Article • Supportive Care in Cancer, January 2008, Springer Science + Business Media

    Fabio Puglisi

  118. Role of pre-surgical breast MRI in the management of invasive breast carcinoma

    Article • The Breast, October 2007, Elsevier

    Fabio Puglisi

  119. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer

    Article • Breast Cancer Research and Treatment, August 2007, Springer Science + Business Media

    Fabio Puglisi

  120. Markers of the uPA System and Common Prognostic Factors in Breast Cancer

    Article • American Journal of Clinical Pathology, July 2007, Oxford University Press (OUP)

    Fabio Puglisi

  121. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly

    Article • Supportive Care in Cancer, April 2007, Springer Science + Business Media

    Fabio Puglisi

  122. Stereotactic vacuum-assisted breast biopsy: results, follow-up and correlation with radiological suspicion

    Article • La radiologia medica, March 2007, Springer Science + Business Media

    Fabio Puglisi

  123. Progress and new standards of care in the management of HER-2 positive breast cancer

    Article • European Journal of Cancer, February 2007, Elsevier

    Fabio Puglisi

  124. Bone Scan for Baseline Staging in Invasive Breast Cancer at the Time of Primary Presentation

    Article • Breast Care, January 2007, Karger Publishers

    Fabio Puglisi

  125. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report

    Article • BMC Cancer, December 2006, Springer Science + Business Media

    Fabio Puglisi

  126. Highlights from the 42nd annual meeting of the American Society of Clinical Oncology

    Article • Expert Opinion on Pharmacotherapy, October 2006, Informa Healthcare

    Fabio Puglisi

  127. Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value

    Article • La radiologia medica, September 2006, Springer Science + Business Media

    Fabio Puglisi

  128. HEX expression and localization in normal mammary gland and breast carcinoma

    Article • BMC Cancer, July 2006, Springer Science + Business Media

    Fabio Puglisi

  129. Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the “do ut des” paradigm)

    Article • Critical Reviews in Oncology/Hematology, July 2006, Elsevier

    Fabio Puglisi

  130. First-Line Treatment of Metastatic Breast Cancer

    Article • American Journal of Cancer, January 2006, Springer Science + Business Media

    Fabio Puglisi

  131. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

    Article • Breast Cancer Research and Treatment, November 2005, Springer Science + Business Media

    Dr Federico Cappuzzo, Fabio Puglisi

  132. Shrinking the Tumor, Shrinking the Patient Sample Size: The Early Disclosure Dilemma

    Article • Journal of Clinical Oncology, September 2005, American Society of Clinical Oncology (ASCO)

    Fabio Puglisi

  133. PTEN and Egr-1 expression in thyroid proliferative lesions

    Article • Cancer Letters, June 2005, Elsevier

    Fabio Puglisi

  134. Topoisomerase IIα and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer

    Article • Cancer Letters, June 2005, Elsevier

    Fabio Puglisi

  135. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications

    Article • Annals of Oncology, February 2005, Elsevier

    Fabio Puglisi

  136. Trastuzumab and Breast Cancer. Are we just Beyond the Prologue of a Fascinating Story?

    Article • Oncology Research and Treatment, January 2005, Karger Publishers

    Fabio Puglisi

  137. Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001)

    Article • Lung Cancer, October 2004, Elsevier

    Fabio Puglisi

  138. d-Dimer and Venous Thromboembolism

    Article • Annals of Internal Medicine, September 2004, American College of Physicians

    Fabio Puglisi

  139. Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil

    Article • British Journal of Cancer, September 2004, Springer Science + Business Media

    Fabio Puglisi

  140. Primary systemic therapy in patients with breast cancer: rationale of use and magnitude of evidence

    Article • Therapy, September 2004, Future Medicine

    Fabio Puglisi

  141. Galectin-3 expression in non-small cell lung carcinoma

    Article • Cancer Letters, August 2004, Elsevier

    Fabio Puglisi

  142. Bone scanning in lung cancer: Pretest probability is of value

    Article • BMJ, July 2004, BMJ

    Fabio Puglisi

  143. What is the effect of systemic anticancer treatment on cognitive function?

    Article • The Lancet Oncology, May 2004, Elsevier

    Fabio Puglisi

  144. Proteomic evaluation of core biopsy specimens from breast lesions

    Article • Cancer Letters, February 2004, Elsevier

    Fabio Puglisi

  145. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to5-fluorouracil in advanced colorectal cancer

    Article • Annals of Oncology, January 2004, Elsevier

    Fabio Puglisi

  146. Taxane-induced nail changes: incidence, clinical presentationand outcome

    Article • Annals of Oncology, February 2003, Elsevier

    Fabio Puglisi

  147. Role of Mammography, Ultrasound and Large Core Biopsy in the Diagnostic Evaluation of Papillary Breast Lesions

    Article • Oncology, January 2003, Karger Publishers

    Fabio Puglisi

  148. Expression and Localization of the Homeodomain-Containing Protein HEX in Human Thyroid Tumors

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2002, Endocrine Society

    Fabio Puglisi

  149. Expression and Localization of the Homeodomain-Containing Protein HEX in Human Thyroid Tumors

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2002, Endocrine Society

    Fabio Puglisi

  150. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas

    Article • Oncology Reports, January 2002, Spandidos Publications

    Fabio Puglisi

  151. Balance between Cell Division and Cell Death as Predictor of Survival in Patients with Non-Small-Cell Lung Cancer

    Article • Oncology, January 2002, Karger Publishers

    Fabio Puglisi

  152. Tamoxifen-Induced Total Alopecia

    Article • Annals of Internal Medicine, June 2001, American College of Physicians

    Fabio Puglisi

  153. Fatigue: A main component of anemia symptomatology

    Article • Seminars in Oncology, April 2001, Elsevier

    Fabio Puglisi

  154. Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas

    Article • Cancer Letters, January 2001, Elsevier

    Fabio Puglisi

  155. Diagnostic accuracy of perforated compression grid approach for mammographically guided core needle biopsy of breast lesions

    Article • Cancer Letters, November 1999, Elsevier

    Fabio Puglisi

  156. Combined yolk sac tumor and adenocarcinoma in a gastric stump

    Article • Cancer, May 1999, Wiley

    Fabio Puglisi

  157. Image-guided core breast biopsy: a suitable method for pre-operative biological characterization of small (pT1) breast carcinomas

    Article • Cancer Letters, November 1998, Elsevier

    Fabio Puglisi

  158. Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma

    Article • Annals of Oncology, May 1998, Elsevier

    Fabio Puglisi

  159. Predictors of Axillary Lymph Node Metastases in Patients with T1 Breast Carcinoma

    Article • Cancer, April 1998, Wiley

    Fabio Puglisi

  160. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung

    Article • Cancer Letters, February 1998, Elsevier

    Fabio Puglisi

  161. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas

    Article • European Journal of Cancer, September 1996, Elsevier

    Fabio Puglisi

  162. Angiogenesis and Tumor Growth

    Article • New England Journal of Medicine, April 1996, New England Journal of Medicine (NEJM/MMS)

    Fabio Puglisi

  163. Molecular Diagnosis of Neoplasms

    Article • New England Journal of Medicine, July 1995, New England Journal of Medicine (NEJM/MMS)

    Fabio Puglisi

  164. Microscopic thymoma and myasthenia gravis.

    Article • Journal of Clinical Pathology, July 1995, BMJ

    Fabio Puglisi